Werkgroep Cardiologische centra Nederland

BaxDUO PREVENT-HF (Recruiting)

A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure
Medicine
Baxdrostat
Population
Heart failure
Phase
III
Starting year
2024

Director of Study

dr. G.C.M. Linssen (Cardioloog)
Almelo, ZGT